Literature DB >> 15102747

Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes.

M J O Toledo1, M T Bahia, V M Veloso, C M Carneiro, G L L Machado-Coelho, C F Alves, H R Martins, R E Cruz, W L Tafuri, M Lana.   

Abstract

The goal of this study was to verify the effect of specific treatment on parasitological and histopathological parameters in mice experimentally infected with different Trypanosoma cruzi clonal genotypes. Twenty cloned stocks were selected, representative of the whole phylogenetic diversity of the protozoan and belonging to the clonal genotypes 19 and 20 (T. cruzi I) and 39 and 32 (T. cruzi II). The stocks were inoculated in 40 BALB/c mice divided into four groups: (i) treated with benznidazole, (ii) treated with itraconazole and (iii and iv) untreated control groups (NT) for each drug, respectively. Seven parameters related to parasitaemia curves and histopathological lesions were analysed. Four during the acute phase (AP) and three during both the AP and chronic phase (CP) of infection. Statistical comparison between benznidazole-treated and NT groups for the biological parameters showed significant differences for all genotypes. Benznidazole treatment led to lower patent period, maximum of parasitaemia, day of maximum parasitaemia and area under the parasitaemia curve for all genotypes analysed. Percentage of positive haemoculture during AP and CP was lower for genotypes 19 and 32. Tissue parasitism (TP) and inflammatory process (IP) during AP were lower for genotypes 19 and 32, respectively. In general, itraconazole treatment induced a smaller reduction in these same parameters between treated and NT animals in relation to benznidazole treatment. Our results indicate that phylogenetic divergence among T. cruzi clonal genotypes must be taken in account in chemotherapy and studies dealing with all aspects of the parasite and the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102747     DOI: 10.1093/jac/dkh224

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.

Authors:  María L Scalise; Eva C Arrúa; Marcela S Rial; Mónica I Esteva; Claudio J Salomon; Laura E Fichera
Journal:  Am J Trop Med Hyg       Date:  2016-05-31       Impact factor: 2.345

2.  Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Juliana Saraiva; Márcio Luis Andrade Silva; Eveline Soares Costa; Ana Carolina Pereira; Jairo Kenupp Bastos; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2010-05-04       Impact factor: 2.289

3.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Authors:  Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

5.  Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites.

Authors:  Guillermo Cruz-Zetina; Rodolfo del Rio-Rodriguez; Angel Ramos-Ligonio; Ruth López; Victor Monteon
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

6.  New method for quantification of Trypanosoma cruzi in animal's tissue in the chronic phase of experimental Chagas' disease.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Miriam Paula Alonso Toldo; Juliana Saraiva; Mariana Bryan Augusto; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

7.  Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.

Authors:  Noelia L Grosso; Jacqueline Bua; Alina E Perrone; Mariela N Gonzalez; Patricia L Bustos; Miriam Postan; Laura E Fichera
Journal:  Exp Parasitol       Date:  2010-05-21       Impact factor: 2.011

8.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

9.  Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.

Authors:  H R Martins; R Moreira Silva; H M S Valadares; M J O Toledo; V M Veloso; D M Vitelli-Avelar; C M Carneiro; G L L Machado-Coelho; M T Bahia; O A Martins-Filho; A M Macedo; M Lana
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

10.  Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of Trypanosoma cruzi.

Authors:  Paula F dos Santos; Jerônimo C Ruiz; Rodrigo P P Soares; Douglas S Moreira; Antônio M Rezende; Edson L Folador; Guilherme Oliveira; Alvaro J Romanha; Silvane M F Murta
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.